Feature | April 30, 2015

High Radiotherapy Dose Improves Prospects for Children with Brain Cancer

Pair of studies find higher dose increases overall survival 11 percent

ependymoma, pediatric, radiotherapy, dose, ESTRO

April 30, 2015 — Two new studies show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival. Results of both studies were presented at the third European Society for Radiotherapy and Oncology (ESTRO) Forum in Barcelona, Spain.

Malignant ependymoma, which develops in the cells that line the hollow cavities of the brain, is normally treated with a combination of surgery and radiotherapy, sometimes with the addition of chemotherapy. Since 2004 a dose of 59.4 Gy has been recommended for pediatric cases worldwide, as opposed to the lower (54 Gy) dose that was in use previously; the studies say adding a radiotherapy boost to this can improve outcome yet further in selected cases.

Ependymoma is the third most common brain tumor in children. With surgery and radiation therapy, the overall five-year survival rate is approximately 70 percent, but individual prognoses differ considerably according to a number of factors — age, extent of surgery, and radiotherapy technique and dose.

Lorenza Gandola, M.D., head of the Pediatric Radiotherapy Unit at the Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, described how her team developed an innovative strategy for children who still had measurable intracranial ependymoma after surgery. In addition to the 59.4 Gy radiotherapy dose to the tumor bed, they added a boost of 8 Gy, divided into two fractions, to the tumor residue. The researchers used a combination of highly sophisticated radiotherapy techniques in order to deliver the radiation dose directly to the remaining malignant tissue while sparing normal brain tissue as much as possible. Twenty-four eligible children (median age 4.5 years) out of the 143 in the Italian project received the radiotherapy boost and 15 of them are still alive without disease progression at a median of 51 months after diagnosis.

"Our strategy contributed significantly to obtaining durable local control of disease in these children, and this is more striking because they already had a poorer prognosis after surgery," Gandola said. "The hypofractionated radiotherapy boost approach represents an effective alternative to surgery in cases where further surgery cannot be performed without the possibility of causing severe and perhaps life-long damage to the child."

No deaths related to the treatment or major toxicity have been reported in the boost group, the researchers said. The technique will now be the subject of an international clinical trial, to be carried out under the auspices of the European Pediatric Oncology Society (SIOP) and planned to start later this year.

"We believe that our research has the potential to improve outcomes in children with poor prognosis ependymoma, and we hope that the SIOP trial will confirm them further to the benefit of such patients," Gandola concluded.

In another presentation, Anne Ducassou, M.D., from the Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France, discussed findings from a study of all 177 children treated for ependymoma in France between 2000 and 2013. The children ranged in age from 1-23, with a median age of five. The researchers studied the characteristic of their disease as revealed by magnetic resonance imaging (MRI) scans, and specifically in those related to metabolism — for example perfusion (the blood flow created in the tumor), and the diffusion of intercellular water molecules, which also reflects the number of cells in the tumor. "We wanted to know whether these metabolic characteristics might have a role in the prognosis of local control of disease and in survival, and whether they might also be able to help us predict relapse, where the disease returns or reoccurs after a period of improvement," Ducassou said.

All radiation oncologists in France who had treated pediatric patients with ependymoma provided information to Ducassou's team. The researchers found that children with localized disease who had been treated with the high radiation dose of 59.4 Gy, in use since 2004, did better than those who had received the lower dose in use until that date. Of the 177 patients included in the study, the estimated overall survival and progression-free survival (where the disease remains but does not get worse) were 90 percent and 67 percent for patients who received a dose above 54 Gy, compared with 79 percent and 52 percent who received a lower dose.

"Our work, which involved a large number of children with ependymoma, has confirmed that the treatment we carry out today is better than it was a few years ago, but there is still much work to be done. For example, we found that children younger than three, and those with more aggressive disease had a poorer outcome, and we need to look further at how we can improve their treatment, as well as identifying other children at high risk of relapse," Ducassou said.

Prof. Philip Poortmans, president of ESTRO, commented: "Cancer in children is luckily rare but, when diagnosed, has a major effect of the lives of not only the patient but also the parents and other people close to the child. Recently, research in childhood cancer has focused mainly on the avoidance of late side effects. However, in cases like that of ependymoma, many patients are still not cured and subsequently die from their disease. Therefore it is important to be able to be able recognize accurately those children who are at high-risk for recurrence, and to intensify their treatment.

"Both studies presented here demonstrate that a clear dose-effect relationship exists for tumor control and survival. While the increase from 54 to 59.4 Gy that was adopted first improves disease control and survival in a population-based study, a new study is planned to confirm the results of increasing the dose by a further 8 Gy, delivered with highly directed radiation therapy techniques that give a very localized dose to the target volume with a low dose to the surrounding normal tissues. We hope that this will bring about even better outcomes for these children."

For more information: www.estro.org

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
Overlay Init